Eriochem

What Eriochem does

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 and headquartered in Colonia Avellaneda, Paraná, Entre Ríos, specializing in the development and manufacturing of generic and supergeneric oncology injectables in liquid and lyophilized forms. The company's commercial portfolio comprises ten branded products covering complex oncology molecules including decitabine, bortezomib, pemetrexed, vinorelbine, leuprolide acetate, oxaliplatin, zoledronic acid, bendamustine, melphalan, and gemcitabine. Its R&D infrastructure includes a dedicated Nanotechnology Research Department and three specialized development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. The company holds 78 patents approved in major regulatory markets worldwide.

Eriochem operates a B2B technology-licensing go-to-market model rather than direct-to-pharmacy sales. Manufacturing is conducted at its Paraná facility under GMP compliance with both US Pharmacopeia (USP) and European Pharmacopeia (EP) standards, supported by a Quality Control function that employs 25% of company personnel and a separate Quality Assurance function that maintains regulatory compliance through internal and external audits. The company has secured Mercosur GMP certification, a positive Turkey Ministry of Health GMP inspection (2025), and markets its products through licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America including the United States. Recent commercial engagement includes participation in CPHI Frankfurt (2025), DCAT New York City (March 2026), and FCE Pharma Brazil (June 2026).

The company's revenue model is built on licensing its proprietary generic and supergeneric formulations to international pharmaceutical partners, who then distribute the products under their own or co-branded labels. Pricing is not publicly disclosed. Eriochem is a privately held entity with no disclosed venture capital, private equity, or public shareholders; in July 2026 it announced changes to its shareholder structure, indicating an active ownership event. The company employs between 101 and 250 people and operates without disclosed subsidiaries, management team profiles, or acquisition activity.

Name

Eriochem

Legal name

ERIOCHEM S.A.

Website

https://eriochem.com.ar

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 that develops and manufactures generic and supergeneric oncology injectables, licensing its formulations to international pharmaceutical partners across Latin America, Asia Pacific, Europe, and North America.

Ownership category

akta.pro rank

Headquarters

HQ city

Parana

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Generic Oncology Pharmaceuticals: Manufacturing and sale of generic oncology medications including branded generics (supergenerics). Revenue generated through product sales to international pharmaceutical partners and distributors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Eriochem is an Argentine pharmaceutical laboratory that develops and manufactures generic and supergeneric injectable oncology medications (liquid and lyophilized formulations). Its R&D division runs a Nanotechnology Research Department and three development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. Products are commercialized internationally through technology licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America.

Product overview

Eriochem S.A. is an Argentine pharmaceutical laboratory specializing in generic oncological medications and super-generics with added-value technology. The company operates as a multi-Latin enterprise with vertical integration, developing and producing high-quality generic cancer medications. Its product portfolio consists of ten branded generic oncology products: Erioxel (Decitabine), Eugene (Bortezomib), Martxel (Pemetrexed), Vinorel (Vinorelbina), Lectrum (Leuprolide Acetate), Goxyral (Oxaliplatin), Eriophos (Zoledronic Acid), Eriotib (Bendamustina), Eriolan (Melphalan), and Eriogem (Gemcitabine). Eriochem's R&D division focuses on nanotechnology and three development teams: controlled-release product development, difficult-to-make generic development, and super-generic development. The company holds 78 patents approved in demanding markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Erioxel®: Generic oncology product containing Decitabine for mantle cell lymphoma and multiple myeloma
• Eugene®
• Martxel®
• Vinorel®
• Lectrum®
• Goxyral®
• Eriophos®
• Eriotib®
• Eriolan®
• Eriogem®

Products and services

• Erioxel®

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• International Pharmaceutical CompaniescoreStrategic or Co-development PartnerEriochem has established multiple strategic alliances with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America. These partnerships involve the granting of technology licenses for proprietary generic oncology medications and registration patents. The company leverages its high quality standards, reliability, and project management efficiency to attract international partners seeking advanced generic pharmaceutical manufacturing capabilities.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cipla: Indian-headquartered global pharmaceutical company with oncology and complex generics portfolios. Directly comparable as a generic injectables manufacturer with emerging markets focus and global licensing/distribution model.
• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with significant injectable generics and oncology portfolios. Comparable to Eriochem in generic injectable manufacturing focus and emerging markets presence through global licensing.
• Intas Pharmaceuticals: Indian-headquartered global pharmaceutical company with a strong specialty generics portfolio including oncology injectables. Directly comparable to Eriochem as a generic injectable manufacturer targeting global markets via licensing and direct sales.
• Dr. Reddy's Laboratories: Major Indian generic pharmaceutical manufacturer with significant oncology injectable presence. Comparable to Eriochem in generic injectable oncology, though operating at substantially larger scale across more therapeutic areas.
• Hikma Pharmaceuticals: Jordanian-headquartered specialty generic injectable manufacturer with global reach. Comparable to Eriochem in injectable generics focus, GMP-certified manufacturing, and licensing-based international distribution.

Regional players

• Eurofarma: Brazilian-headquartered Latin American pharmaceutical company with oncology generics portfolio. Regional peer comparable to Eriochem in Latin American market presence and emerging market focus.
• Aspen Pharmacare: South African-headquartered generic pharmaceutical manufacturer with global emerging markets presence. Comparable as a generic oncology manufacturer serving emerging markets through licensing partnerships.

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with extensive injectable and oncology portfolios. Broad incumbent comparable in generic injectables manufacturing but operating at vastly larger scale and direct distribution.
• Sandoz (Novartis): Global generic pharmaceuticals division with significant injectable and oncology presence. Broad incumbent comparable to Eriochem in generic injectables manufacturing, with substantially deeper resources and direct market access.
• Fresenius Kabi: Global pharmaceutical company with extensive injectable generics portfolio including oncology. Broader incumbent with deeper resources and direct sales infrastructure compared to Eriochem's licensing model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eriochem

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eriochem